Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Chem Res Toxicol ; 34(3): 672-674, 2021 03 15.
Article in English | MEDLINE | ID: covidwho-997760

ABSTRACT

As COVID-19 swept across the world, it created a global pandemic and an unpredictable and challenging job market. This article discusses the future of the 2020-2021 job market in both academia and industry in the midst and aftermath of this pandemic.


Subject(s)
Biopharmaceutics/economics , COVID-19/economics , Chemical Industry/economics , Universities/economics , Biopharmaceutics/organization & administration , Biopharmaceutics/trends , COVID-19/epidemiology , Chemical Industry/organization & administration , Humans , Pandemics , Research/economics , Research/organization & administration , SARS-CoV-2 , Social Networking , Unemployment , Universities/organization & administration , Workforce
2.
FEBS Lett ; 594(11): 1647-1650, 2020 06.
Article in English | MEDLINE | ID: covidwho-624467

ABSTRACT

The recent resignation of the President of the European Research Council (ERC) Mauro Ferrari has opened a wide discussion both on the method of designation of the President of the ERC and on the validity of the different funding mechanisms for scientific research. From this point of view, Sars-CoV-2 was not only responsible for the pandemic, but also triggered a debate on an alleged primacy of applied research over the fundamental research.


Subject(s)
Societies, Scientific/organization & administration , Europe , Research/economics , Societies, Scientific/economics
3.
Daru ; 28(2): 799-805, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-621499

ABSTRACT

BACKGROUND: The novel coronavirus disease 2019 (COVID-19) was characterized as a global pandemic by the WHO on March 11th, 2020. This pandemic had major effects on the health market, the pharmaceutical sector, and was associated with considerable impacts; which may appear in short and long-term time-horizon and need identification and appropriate planning to reduce their socio-economic burden. OBJECTIVES: Current short communication study assessed pharmaceutical market crisis during the COVID-19 era; discussing short- and long-term impacts of the pandemic on the pharmaceutical sector. RESULTS: Short-term impacts of COVID-19 pandemic includes demand changes, regulation revisions, research and development process changes and the shift towards tele-communication and tele-medicine. In addition, industry growth slow-down, approval delays, moving towards self-sufficiency in pharm-production supply chain and trend changes in consumption of health-market products along with ethical dilemma could be anticipated as long-term impacts of COVID-19 pandemic on pharmaceutical sector in both global and local levels. CONCLUSION: The pandemic of COVID-19 poses considerable crisis on the health markets, including the pharmaceutical sector; and identification of these effects, may guide policy-makers towards more evidence-informed planning to overcome accompanying challenges. Graphical abstract .


Subject(s)
COVID-19/economics , Drug Industry/economics , Pharmaceutical Preparations/economics , Research/economics , Drug Industry/trends , Humans , Pharmaceutical Preparations/supply & distribution , Policy Making , Research/trends , Telemedicine/trends , Time Factors
6.
J Infect Dis ; 222(3): 356-361, 2020 07 06.
Article in English | MEDLINE | ID: covidwho-425892

ABSTRACT

Trials are in development and underway to examine potential interventions for treatment and prophylaxis of coronavirus disease 2019 (COVID-19). How should we think about offering payment to participants in these trials? Payment for research participation is ethically contentious even under ideal circumstances. Here, we review 3 functions of research payment-reimbursement, compensation, and incentive-and identify heightened and novel ethical concerns in the context of a global pandemic. We argue that COVID-19 trial participants should usually be offered reimbursement for research-related expenses, and compensation for their time and effort, as for other types of research under usual circumstances. Given increased risk of undue influence against pandemic background conditions, incentive payment should be avoided unless essential to recruitment and retention in important trials whose social value outweighs this risk. Where essential, however, incentives can be ethically permissible, so long as reasonable efforts are made to minimize the possibility of undue influence.


Subject(s)
Clinical Trials as Topic/economics , Coronavirus Infections/therapy , Healthy Volunteers , Pneumonia, Viral/therapy , COVID-19 , Clinical Trials as Topic/ethics , Compensation and Redress/ethics , Coronavirus Infections/prevention & control , Humans , Motivation/ethics , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Research/economics
SELECTION OF CITATIONS
SEARCH DETAIL